INTECH Investment Management’s Nurix Therapeutics NRIX Stock Holding History

INTECH Investment Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$450K	Sell	18,559 -4,254	-19%	-$72.5K	﹤0.01%	1392
2026 Q1	$354K	Sell	22,813 -2,202	-9%	-$36.5K	﹤0.01%	1496
2025 Q4	$475K	Sell	25,015 -8,264	-25%	-$119K	﹤0.01%	1534
2025 Q3	$307K	Sell	33,279 -9,074	-21%	-$94.2K	﹤0.01%	1814
2025 Q2	$482K	Sell	42,353 -14,417	-25%	-$156K	﹤0.01%	1624
2025 Q1	$674K	Buy	56,770 +20,934	+58%	+$350K	0.01%	1449
2024 Q4	$675K	Buy	35,836 +16,935	+90%	+$388K	0.01%	1384
2024 Q3	$425K	Buy	+18,901	New	+$428K	﹤0.01%	1317

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

INTECH Investment Management's NRIX Position: Q2 2026 in Review

INTECH Investment Management reduced its Nurix Therapeutics (NRIX) stake by 19% in Q2 2026, selling an estimated $72.5K and leaving 18,559 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #1392.

INTECH Investment Management first reported a position in NRIX in Q3 2024 and has held it in 8 quarters since. The position peaked at $675K in Q4 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

INTECH Investment Management held 18,559 shares of Nurix Therapeutics worth $450K as of Q2 2026.
INTECH Investment Management sold 4,254 Nurix Therapeutics shares in Q2 2026, an estimated $72.5K.
Nurix Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #1392 holding.
INTECH Investment Management first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's Nurix Therapeutics position peaked at $675K in Q4 2024.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.